<p>Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）- HC Wainwright 的股票研究分析师在 11 月 13 日星期四发布的报告中下调了 Journey Medical 2025 财年的每股收益（EPS）预期。HC Wainwright 的分析师 B. Folkes 现在预测该公司将发布每股收益（$0.53），低于之前的预期（$0.45）。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 13.00 美元。市场普遍预期 Journey Medical 当前全年的每股收益为（$1.02）。HC Wainwright 还对 Journey Medical 2025 年第四季度的每股收益预期为（$0.10）。</p>
<p>其他几家券商也对 DERM 发表了看法。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Journey Medical 股票的 “卖出（d-）” 评级。Zacks Research 在 10 月 13 日星期一的报告中将 Journey Medical 的评级从 “强烈卖出” 上调至 “持有”。最后，Lake Street Capital 在 8 月 13 日星期三的研究报告中将 Journey Medical 的目标价从 9.00 美元上调至 13.00 美元，并给予该股票 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 12.17 美元。</p>
<p>获取 <strong>Journey Medical</strong> 的提醒：</p>
<p><strong>查看我们对 Journey Medical 的最新股票分析</strong></p>
<h2>Journey Medical 股票表现</h2>
<p>纳斯达克 DERM 周一开盘价为 7.89 美元。该股票的 50 日简单移动平均线为 7.65 美元，200 日简单移动平均线为 7.32 美元。该公司的流动比率为 1.42，速动比率为 1.12，债务与股本比率为 0.75。该股票的市值为 2.0759 亿美元，市盈率为 -22.54，贝塔值为 0.80。Journey Medical 的 12 个月低点为 3.54 美元，12 个月高点为 9.40 美元。</p>
<p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近在 11 月 12 日星期三发布了季度财报。该公司报告的每股收益为（$0.09），低于市场共识预期的（$0.08）$0.01。Journey Medical 的股本回报率为 -39.94%，净利润率为 -14.58%。该业务在本季度的收入为 1763 万美元，而分析师的预期为 1885 万美元。</p>
<h2>Journey Medical 的机构交易</h2>
<p>一些大型投资者最近对 DERM 的持仓进行了调整。Wasatch Advisors LP 在第二季度将其在 Journey Medical 的持股增加了 23.8%。Wasatch Advisors LP 目前拥有 1,152,059 股该公司的股票，价值 8,272,000 美元，此前在上个季度增持了 221,456 股。Geode Capital Management LLC 在第二季度将其在 Journey Medical 的持股增加了 130.7%。Geode Capital Management LLC 目前拥有 262,353 股该公司的股票，价值 1,884,000 美元，此前在上个季度增持了 148,612 股。Sheets Smith Investment Management 在第三季度购买了 Journey Medical 的新股份，价值 946,000 美元。Essex Investment Management Co. LLC 在第三季度将其在 Journey Medical 的持股增加了 55.1%。Essex Investment Management Co. LLC 目前拥有 354,021 股该公司的股票，价值 2,521,000 美元，此前在上个季度增持了 125,818 股。最后，Vanguard Group Inc. 在第三季度将其在 Journey Medical 的持股增加了 8.9%。Vanguard Group Inc. 目前拥有 615,229 股该公司的股票，价值 4,380,000 美元，此前在上个季度增持了 50,241 股。7.25% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>关于 Journey Medical</h2>
<p>（获取免费报告）</p>
<p>Journey Medical Corporation 专注于开发和商业化用于治疗美国皮肤病的药品。该公司的市场产品包括 Qbrexza，一种用于治疗原发性腋下多汗症的药用湿巾；Accutane，一种用于治疗严重顽固性结节性痤疮的口服异维 A 酸药物；以及 Amzeeq，一种用于治疗中度至重度非结节性痤疮炎症病变的米诺环素外用制剂。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Journey Medical</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>4 只适合冬季消费的冷天气股票</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>Disney 股票下跌——收益是否为 YouTube TV 和解铺平道路？</li>
<li>投资者需要了解即将上市的 IPO</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Journey Medical 吗？</h2>
<p>在考虑 Journey Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Journey Medical 并不在名单上。</p>
<p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DERM

<p>HC Wainwright 已将 Journey Medical 的 2025 财年每股收益预测从 ($0.45) 下调至 ($0.53)，维持 “买入” 评级，目标价为 $13.00。该股票在分析师中获得了混合评级，普遍评级为 “持有”，平均目标价为 $12.17。Journey Medical 最近的季度收益未能达到预期，股票在纳斯达克开盘价为 $7.89。机构投资者正在调整在该公司的持仓</p>

<p>Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 EPS estimates for shares of Journey Medical in a report released on Thursday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.53) per share for the year, down from their previous estimate of ($0.45). HC Wainwright currently has a &#34;Buy&#34; rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q4 2025 earnings at ($0.10) EPS.</p>
<div class="lb-trans"><p>Journey Medical Corporation（纳斯达克代码：DERM - 免费报告）- HC Wainwright 的股票研究分析师在 11 月 13 日星期四发布的报告中下调了 Journey Medical 2025 财年的每股收益（EPS）预期。HC Wainwright 的分析师 B. Folkes 现在预测该公司将发布每股收益（$0.53），低于之前的预期（$0.45）。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 13.00 美元。市场普遍预期 Journey Medical 当前全年的每股收益为（$1.02）。HC Wainwright 还对 Journey Medical 2025 年第四季度的每股收益预期为（$0.10）。</p>
</div><p>Several other brokerages have also weighed in on DERM. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Journey Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Finally, Lake Street Capital upped their price target on Journey Medical from $9.00 to $13.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $12.17.</p>
<div class="lb-trans"><p>其他几家券商也对 DERM 发表了看法。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Journey Medical 股票的 “卖出（d-）” 评级。Zacks Research 在 10 月 13 日星期一的报告中将 Journey Medical 的评级从 “强烈卖出” 上调至 “持有”。最后，Lake Street Capital 在 8 月 13 日星期三的研究报告中将 Journey Medical 的目标价从 9.00 美元上调至 13.00 美元，并给予该股票 “买入” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 12.17 美元。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Journey Medical</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on Journey Medical</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Journey Medical 的最新股票分析</strong></p>
</div><h2>Journey Medical Stock Performance</h2>
<div class="lb-trans"><h2>Journey Medical 股票表现</h2>
</div><p>NASDAQ DERM opened at $7.89 on Monday. The stock has a fifty day simple moving average of $7.65 and a 200-day simple moving average of $7.32. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75. The stock has a market cap of $207.59 million, a PE ratio of -22.54 and a beta of 0.80. Journey Medical has a twelve month low of $3.54 and a twelve month high of $9.40.</p>
<div class="lb-trans"><p>纳斯达克 DERM 周一开盘价为 7.89 美元。该股票的 50 日简单移动平均线为 7.65 美元，200 日简单移动平均线为 7.32 美元。该公司的流动比率为 1.42，速动比率为 1.12，债务与股本比率为 0.75。该股票的市值为 2.0759 亿美元，市盈率为 -22.54，贝塔值为 0.80。Journey Medical 的 12 个月低点为 3.54 美元，12 个月高点为 9.40 美元。</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Journey Medical had a negative return on equity of 39.94% and a negative net margin of 14.58%.The business had revenue of $17.63 million during the quarter, compared to analysts' expectations of $18.85 million.</p>
<div class="lb-trans"><p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近在 11 月 12 日星期三发布了季度财报。该公司报告的每股收益为（$0.09），低于市场共识预期的（$0.08）$0.01。Journey Medical 的股本回报率为 -39.94%，净利润率为 -14.58%。该业务在本季度的收入为 1763 万美元，而分析师的预期为 1885 万美元。</p>
</div><h2>Institutional Trading of Journey Medical</h2>
<div class="lb-trans"><h2>Journey Medical 的机构交易</h2>
</div><p>A number of large investors have recently made changes to their positions in DERM. Wasatch Advisors LP raised its holdings in Journey Medical by 23.8% in the second quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock valued at $8,272,000 after acquiring an additional 221,456 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Journey Medical by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock valued at $1,884,000 after purchasing an additional 148,612 shares in the last quarter. Sheets Smith Investment Management purchased a new stake in shares of Journey Medical during the 3rd quarter worth $946,000. Essex Investment Management Co. LLC lifted its position in shares of Journey Medical by 55.1% during the 3rd quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company's stock worth $2,521,000 after purchasing an additional 125,818 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Journey Medical by 8.9% during the third quarter. Vanguard Group Inc. now owns 615,229 shares of the company's stock worth $4,380,000 after purchasing an additional 50,241 shares in the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近对 DERM 的持仓进行了调整。Wasatch Advisors LP 在第二季度将其在 Journey Medical 的持股增加了 23.8%。Wasatch Advisors LP 目前拥有 1,152,059 股该公司的股票，价值 8,272,000 美元，此前在上个季度增持了 221,456 股。Geode Capital Management LLC 在第二季度将其在 Journey Medical 的持股增加了 130.7%。Geode Capital Management LLC 目前拥有 262,353 股该公司的股票，价值 1,884,000 美元，此前在上个季度增持了 148,612 股。Sheets Smith Investment Management 在第三季度购买了 Journey Medical 的新股份，价值 946,000 美元。Essex Investment Management Co. LLC 在第三季度将其在 Journey Medical 的持股增加了 55.1%。Essex Investment Management Co. LLC 目前拥有 354,021 股该公司的股票，价值 2,521,000 美元，此前在上个季度增持了 125,818 股。最后，Vanguard Group Inc. 在第三季度将其在 Journey Medical 的持股增加了 8.9%。Vanguard Group Inc. 目前拥有 615,229 股该公司的股票，价值 4,380,000 美元，此前在上个季度增持了 50,241 股。7.25% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>About Journey Medical</h2>
<div class="lb-trans"><h2>关于 Journey Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</p>
<div class="lb-trans"><p>Journey Medical Corporation 专注于开发和商业化用于治疗美国皮肤病的药品。该公司的市场产品包括 Qbrexza，一种用于治疗原发性腋下多汗症的药用湿巾；Accutane，一种用于治疗严重顽固性结节性痤疮的口服异维 A 酸药物；以及 Amzeeq，一种用于治疗中度至重度非结节性痤疮炎症病变的米诺环素外用制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Journey Medical</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>4 只适合冬季消费的冷天气股票</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>Disney 股票下跌——收益是否为 YouTube TV 和解铺平道路？</li>
<li>投资者需要了解即将上市的 IPO</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Journey Medical 吗？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Journey Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Journey Medical 并不在名单上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师下调了 Journey Medical 的 2025 财年每股收益预测